Ki-67表达对髓母细胞瘤患者预后的影响  

Influence of Ki-67 on the prognosis of patients with medulloblastoma

作　　者：李克[1] 耿俊杰[1] 张振宇[1] 刘献志[1] 张智峰[1] Li Ke;Geng Junjie;Zhang Zhenyu;Liu Xianzhi;Zhang Zhifeng(Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China)

机构地区：[1]郑州大学第一附属医院神经外科,450052

出　　处：《中国实用医刊》2019年第11期1-3,共3页Chinese Journal of Practical Medicine

基　　金：国家自然科学基金项目(81702465).

摘　　要：目的探讨Ki-67对髓母细胞瘤患者预后的影响。方法回顾性分析2009年1月至2018年1月郑州大学第一附属医院收治的经术后病理结果证实为髓母细胞瘤的患者109例,采用Kaplan-Meier法计算总生存期和无进展生存期的生存率,各因素生存率的比较采用Log-rank检验,应用Cox比例风险模型评估法行多因素分析。结果与Ki-67≤50%的髓母细胞瘤患者相比,Ki-67>50%的髓母细胞瘤患者的无进展生存期(P=0.006)及总生存期(P=0.017)均缩短;Ki-67是影响髓母细胞瘤患者预后的独立危险因素。结论随着Ki-67的升高,髓母细胞瘤患者的预后越差,Ki-67是髓母细胞瘤患者潜在的预后标志物。Objective To investigate the effects of Ki-67 on the prognosis of patients with medulloblastoma. Methods A total of 109 patients with medulloblastoma confirmed by postoperative pathology in the First Affiliated Hospital of Zhengzhou University from January 2009 to January 2018 were enrolled in the study. Kaplan-Meier method was used to calculate the survival rates of the overall survival (OS) and progression-free survival (PFS). The survival rates of these factors were compared by Log-rank test. The Cox proportional hazard model was evaluated by multivariate analysis. Results The progression-free survival (P=0.006) and total survival (P=0.017) of medulloblastoma patients with Ki-67>50% were shorter than those of medulloblastoma patients with Ki-67< 50%. Ki-67 was an independent risk factor influencing prognosis of patients with medulloblastoma. Conclusions With the increase in Ki-67, prognosis of patients with medulloblastoma get worse. Ki-67 is a potential prognostic marker for patients with medulloblastoma.

关 键 词：KI-67 髓母细胞瘤 预后 生存期 

分 类 号：R739.4[医药卫生—肿瘤]